Mar Vista Investment Partners LLC Purchases 4,655 Shares of Johnson & Johnson $JNJ

Mar Vista Investment Partners LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 189,441 shares of the company’s stock after purchasing an additional 4,655 shares during the quarter. Johnson & Johnson makes up about 2.2% of Mar Vista Investment Partners LLC’s investment portfolio, making the stock its 26th largest position. Mar Vista Investment Partners LLC’s holdings in Johnson & Johnson were worth $28,937,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at about $48,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $65,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Bank of America boosted their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Scotiabank began coverage on shares of Johnson & Johnson in a research note on Thursday. They issued a “sector outperform” rating and a $230.00 target price for the company. Finally, Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $196.00 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $197.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $185.81 and its 200-day moving average is $170.04. The firm has a market capitalization of $472.22 billion, a price-to-earnings ratio of 18.92, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.